LF 984

Drug Profile

LF 984

Latest Information Update: 30 Mar 2001

Price : $50

At a glance

  • Originator Groupe Fournier
  • Class
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Fibrosis

Most Recent Events

  • 30 Mar 2001 Discontinued-Preclinical for Fibrosis in France (Unknown route)
  • 29 Dec 1999 LF 984 is available for licensing (http://www.groupe-fournier.com/)
  • 15 Nov 1999 Preclinical development for Fibrosis in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top